Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Trading Down 7.1%

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM)’s share price was down 7.1% on Thursday . The stock traded as low as $6.47 and last traded at $6.56. Approximately 327,591 shares traded hands during mid-day trading, an increase of 1% from the average daily volume of 324,656 shares. The stock had previously closed at $7.06.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ATNM. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Finally, Maxim Group boosted their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Price Performance

The firm has a market cap of $201.98 million, a price-to-earnings ratio of -3.75 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million during the quarter. As a group, equities research analysts predict that Actinium Pharmaceuticals, Inc. will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ATNM. Creative Financial Designs Inc. ADV increased its position in Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Sanders Morris Harris LLC bought a new stake in shares of Actinium Pharmaceuticals during the first quarter worth $78,000. Finally, Brandywine Global Investment Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth $1,033,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.